NO20045535L - Fremgangsmate for a fremme roykeavvenning - Google Patents

Fremgangsmate for a fremme roykeavvenning

Info

Publication number
NO20045535L
NO20045535L NO20045535A NO20045535A NO20045535L NO 20045535 L NO20045535 L NO 20045535L NO 20045535 A NO20045535 A NO 20045535A NO 20045535 A NO20045535 A NO 20045535A NO 20045535 L NO20045535 L NO 20045535L
Authority
NO
Norway
Prior art keywords
smoking cessation
procedure
promoting smoking
promoting
reboxetine
Prior art date
Application number
NO20045535A
Other languages
English (en)
Inventor
Erik Ho Fong Wong
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20045535L publication Critical patent/NO20045535L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Anvendelsen av reboxetin i kombinasjon med et røykeavvenningsforsterkende middel for fremme av røykeavvenning beskrives. Videre beskrives en blanding som omfatter reboxetin og et røykeavvennings-forsterkende middel for bruk til fremme av røykeavvenning. Eksempler på de røykeavvennings-forsterkende midler er nikotin, et antidepressivum, en nikotinreseptorantagonist og en opioidantagonist.
NO20045535A 2002-07-01 2004-12-17 Fremgangsmate for a fremme roykeavvenning NO20045535L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39289302P 2002-07-01 2002-07-01
PCT/US2003/016232 WO2004002463A2 (en) 2002-07-01 2003-06-26 Method of promoting smoking cessation

Publications (1)

Publication Number Publication Date
NO20045535L true NO20045535L (no) 2005-01-27

Family

ID=30000949

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045535A NO20045535L (no) 2002-07-01 2004-12-17 Fremgangsmate for a fremme roykeavvenning

Country Status (22)

Country Link
US (1) US20040102440A1 (no)
EP (1) EP1534254A2 (no)
JP (1) JP2005531631A (no)
CN (1) CN1665511A (no)
AP (1) AP2004003188A0 (no)
AU (1) AU2003253609A1 (no)
BR (1) BR0312293A (no)
CA (1) CA2491549A1 (no)
EA (1) EA200401584A1 (no)
EC (1) ECSP045517A (no)
HR (1) HRP20041194A2 (no)
IL (1) IL165882A0 (no)
IS (1) IS7600A (no)
MA (1) MA27597A1 (no)
MX (1) MXPA05000296A (no)
NO (1) NO20045535L (no)
OA (1) OA12878A (no)
PL (1) PL373620A1 (no)
RS (1) RS115204A (no)
TN (1) TNSN04267A1 (no)
WO (1) WO2004002463A2 (no)
ZA (1) ZA200410339B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
EP1578422B1 (en) 2002-12-20 2007-04-11 NicoNovum AB A physically and chemically stable nicotine and micorcrystalline cellulose containing particulate material
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7241805B2 (en) 2005-06-27 2007-07-10 Biovail Laboratories, Inc. Modified release formulations of a bupropion salt
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
WO2008060964A2 (en) 2006-11-09 2008-05-22 Orexigen Therapeutics, Inc. Unit dosage package and methods for administering weight loss medications
EP2170274A1 (en) * 2007-07-02 2010-04-07 Technion Research and Development Foundation, Ltd. Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20110046116A1 (en) * 2009-08-20 2011-02-24 Cukrowski Walter J Sedative for use during eye surgery
WO2011041451A2 (en) * 2009-09-30 2011-04-07 Harlan Clayton Bieley Smoking cessation with body weight maintenance and nutritional supplement
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym
EP3057596A4 (en) * 2013-10-14 2017-03-29 Palmaya Pty Ltd Compositions and methods of administering same
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CN104381577A (zh) * 2014-11-18 2015-03-04 安徽润康保健食品有限公司 一种具有戒烟功能的口香糖
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US12465611B2 (en) 2019-02-17 2025-11-11 Neurawell Therapeutics Compositions and methods for treatment of depression and other disorders
US12616702B2 (en) 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200001049A1 (ru) * 1998-04-09 2001-04-23 Фармация Энд Апджон Компани Новые способы лечения нервных расстройств
BR9909559A (pt) * 1998-05-08 2000-12-19 Upjohn Co Novas combinações de drogas
ATE305788T1 (de) * 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
DE10004547A1 (de) * 2000-02-02 2001-08-09 Liedtke Pharmed Gmbh Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe

Also Published As

Publication number Publication date
ECSP045517A (es) 2005-03-10
EA200401584A1 (ru) 2005-08-25
AU2003253609A1 (en) 2004-01-19
JP2005531631A (ja) 2005-10-20
BR0312293A (pt) 2005-04-12
IS7600A (is) 2004-12-16
CN1665511A (zh) 2005-09-07
HRP20041194A2 (en) 2005-06-30
PL373620A1 (en) 2005-09-05
WO2004002463A2 (en) 2004-01-08
US20040102440A1 (en) 2004-05-27
RS115204A (sr) 2007-02-05
MXPA05000296A (es) 2005-08-19
TNSN04267A1 (fr) 2007-03-12
MA27597A1 (fr) 2005-11-01
WO2004002463A3 (en) 2004-02-19
ZA200410339B (en) 2006-07-26
IL165882A0 (en) 2006-01-15
AP2004003188A0 (en) 2004-12-31
EP1534254A2 (en) 2005-06-01
CA2491549A1 (en) 2004-01-08
OA12878A (en) 2006-09-15

Similar Documents

Publication Publication Date Title
EA200401584A1 (ru) Способ содействия прекращению курения
DE60334015D1 (de) Pyridopyrrolizin- und pyridoindolizinderivate
NO20081250L (no) Kombinasjon av hypnotisk middel med langtidsvirkning og hypnotisk middel med korttidsvirkning, samt terapeutisk anvendelse av samme
AU2002344951A1 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
EE200200217A (et) Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
BR0313233A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, e, composição farmacêutica
UA90695C2 (en) Potentiators of glutamate receptors
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
SG167664A1 (en) 2,4-pyrimidinediamine compounds and their uses
HUP0301122A2 (hu) Gyógyszerkombinációk és gasztrointesztinális rendellenességek kezelésében való alkalmazásuk
ATE435206T1 (de) Heteroarylsulfonylstilbene als 5-ht2a- antagonisten
GEP20104962B (en) Fused heterocyclic compounds
DE60329330D1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
MY146549A (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
ECSP077277A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
MY140886A (en) Piperazinyl and diazapanyl benzamides and benzthioamides
HUP9800938A2 (hu) NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
EA200700367A1 (ru) Новые производные 4-бензилиденпиперидина
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
DK1581538T3 (da) Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet
MXPA05011212A (es) Derivados de indeno como agentes farmaceuticos.
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
UA87122C2 (ru) Агонисты рецепторов глюкагонподобного пептида-1, их применение и способ получения
EA200200765A1 (ru) Способ уменьшения или прекращения курения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application